Tag Archive for: liraglutide

The European Medicines Agency announced on Friday that it has found no causal association between GLP-1 receptor agonists—a popular class of weight-loss treatments that include Novo Nordisk’s Wegovy (semaglutide)—and the risks of suicidal thoughts and actions.

GLP-1 receptor agonists—a popular drug class that includes Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide)—do not appear to increase the risk of thyroid cancer, according to a new study published Wednesday in The BMJ.

The European Medicines Agency is set to review several diabetes and weight-loss treatments this week in connection with potential increased risk of suicidal ideation and self-harm, according to a draft agenda document of the agency’s Pharmacovigilance Risk Assessment Committee.

Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.

The Medicines and Healthcare products Regulatory Agency said AstraZeneca’s GLP-1 drug for type 2 diabetes, called exenatide and marketed as Bydureon, was also included in the review.

The European Medicines Agency (EMA) is probing Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland’s health regulator flagged three cases of patients on the drugs thinking about suicide or self-harm.

The request to consider obesity drugs was submitted by three doctors and a researcher in the United States and covers the active ingredient liraglutide in Novo Nordisk’s obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions.